In addition to the overall mutation burden, TMB-related specific mutations such as MGA [54], EPHA5, [55], CTNNA2 [56], and co-mutation of FAT3 and LRP1B [57] have been found as novel predictive biomarkers for ICIs response in nonsquamous NSCLC or LUSD. The gene discussed is CTNNA2; the disease is non-small cell lung carcinoma.